Alexion Pharmaceuticals Inc (ALXN)

126.91
NASDAQ : Health Care
Prev Close 126.91
Day Low/High 0.00 / 0.00
52 Wk Low/High 109.12 / 157.02
Avg Volume 1.94M
Exchange NASDAQ
Shares Outstanding 225.15M
Market Cap 27.18B
EPS 1.80
P/E Ratio 68.60
Div & Yield N.A. (N.A)

Latest News

Biotech Movers: Pacific Biosciences Falls After Net Loss Spikes

Biotech Movers: Pacific Biosciences Falls After Net Loss Spikes

Pacific Biosciences of California, Alexion Pharmaceuticals and Arena Pharmaceuticals were among the biotech stock movers in premarket trading on Thursday.

Making Sense of Thursday's Flood of Biotech and Pharma Earnings Reports

Making Sense of Thursday's Flood of Biotech and Pharma Earnings Reports

A guide to keep track of all the companies reporting first quarter financial results today -- making sense of what's important and disregarding what's not.

Alexion Reports First Quarter 2017 Results

Alexion Reports First Quarter 2017 Results

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) today announced financial results for the first quarter of 2017.

Johnson & Johnson's Weak Pharma Revenue Could Spell Doom for Rest of Sector

Johnson & Johnson's Weak Pharma Revenue Could Spell Doom for Rest of Sector

The New Brunswick, N.J.-based company noted that its pharma sales dipped due to weakness in the U.S. compared to other markets.

Alexion To Report First Quarter 2017 Results On Thursday, April 27, 2017

Alexion To Report First Quarter 2017 Results On Thursday, April 27, 2017

Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that the Company will report its financial results for the first quarter ended March 31, 2017 on Thursday, April 27, 2017 before the US financial markets open.

Why AbbVie Will be an Incredible Money-Making Machine in an Overvalued Stock Market

Why AbbVie Will be an Incredible Money-Making Machine in an Overvalued Stock Market

The pharmaceutical giant has an attractive yield supported by double-digit earnings growth.

Alexion Pharma, Still Recovering From Boardroom Troubles, Appoints New CEO

Alexion Pharma, Still Recovering From Boardroom Troubles, Appoints New CEO

Ludwig Hantson takes over the top Alexion job after serving as CEO of Baxalta, which he helped sell to Shire for $32 billion.

Ludwig N. Hantson, Ph.D. (Photo: Business Wire)

Ludwig N. Hantson, Ph.D. (Photo: Business Wire)

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that its Board of Directors has appointed Ludwig N.

Biotech Premarket Movers: Insys, Ultragenyx, Alexion

Biotech Premarket Movers: Insys, Ultragenyx, Alexion

Insys Therapeutics, Ultragenyx Pharmaceutical and Alexion Pharmaceuticals were among the biotech stock movers in premarket trading on Thursday.

Alexion Submits Application In Japan For Soliris® (Eculizumab) As A Potential Treatment For Patients With Refractory Generalized Myasthenia Gravis (gMG)

Alexion Submits Application In Japan For Soliris® (Eculizumab) As A Potential Treatment For Patients With Refractory Generalized Myasthenia Gravis (gMG)

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) announced today that it has submitted an application to Japan's Ministry of Labour and Welfare (MHLW) to extend the indication for Soliris ® (eculizumab) as a potential...

Alexion Pharmaceuticals Cuts 7% of Workforce

Alexion Pharmaceuticals Cuts 7% of Workforce

Alexion Pharmaceuticals is restructuring its business.

Celgene's Deep Pipeline Can Reassure Investors

Celgene's Deep Pipeline Can Reassure Investors

This biotech company is trading at a bargain compared to its peer group.

FDA Accepts SBLA Filing Of Soliris® (Eculizumab) As A Potential Treatment For Patients With Refractory Generalized Myasthenia Gravis (gMG)

FDA Accepts SBLA Filing Of Soliris® (Eculizumab) As A Potential Treatment For Patients With Refractory Generalized Myasthenia Gravis (gMG)

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) announced today that the U.

Pharma, Biotech Stocks Fall on Trump Tweets, GOP Health Care Plan

Pharma, Biotech Stocks Fall on Trump Tweets, GOP Health Care Plan

Investors are deciding what to make of an impending overhaul of the American health care system in the wake of legislative progress out of Washington.

Alexion To Present At Upcoming Investor Conferences

Alexion To Present At Upcoming Investor Conferences

Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that management will present at two upcoming investor conferences: Cowen and Company 37th Annual Health Care Conference in Boston on Monday, March 6, 2017...

Alexion Pharma's Bloated Blockbuster Deal Still Haunts

Alexion Pharma's Bloated Blockbuster Deal Still Haunts

Less than two years later, Alexion is not getting the bang for the mega-bucks it put up for Synageva.

Alexion's Billion Dollar Deal Is Largely Wasted

Alexion's Billion Dollar Deal Is Largely Wasted

Alexion paid $8.4 billion to acquire Synageva in hopes that its leading rare disease drug would become a billion-dollar product.

Biotech Premarket Movers: Progenics, Alexion, BioCryst

Biotech Premarket Movers: Progenics, Alexion, BioCryst

Progenics, Alexion and BioCryst were among the biotech stock movers in premarket trading on Thursday.

Alexion Reports Fourth Quarter And Full Year 2016 Results And Provides Financial Guidance For 2017

Alexion Reports Fourth Quarter And Full Year 2016 Results And Provides Financial Guidance For 2017

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) today announced financial results for the fourth quarter and full year of 2016.

Week Ahead: Federal Reserve Officials, Major Economic Data to Drive Market Movement

Week Ahead: Federal Reserve Officials, Major Economic Data to Drive Market Movement

Fed Chair Janet Yellen will give her two-day semiannual monetary policy testimony, while major economic data will drive markets.

Alexion Pharmaceuticals To Report Fourth Quarter And Full Year 2016 Results On Thursday, February 16, 2017

Alexion Pharmaceuticals To Report Fourth Quarter And Full Year 2016 Results On Thursday, February 16, 2017

Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that the Company will report its financial results for the fourth quarter and full year ended December 31, 2016 on Thursday, February 16, 2017 before the US...

Here Is Why Red-Hot Alexion Is Only Suitable for Risk Takers Now

Here Is Why Red-Hot Alexion Is Only Suitable for Risk Takers Now

This drug maker has risen more than 17% this year. But investors may want to say cautious, unless they are super-aggressive.

Monday's Sights, Sounds and Biotech Buzz From the J.P. Morgan Healthcare Conference

Monday's Sights, Sounds and Biotech Buzz From the J.P. Morgan Healthcare Conference

The $5.2 billion takeout of Ariad Pharma was the biggest news from the closely followed healthcare conference.

Bullish and Bearish Reversals in the Market

Bullish and Bearish Reversals in the Market

These companies show signs of a change of direction.

Alexion Submits U.S. And EU Applications Seeking Approval Of Soliris® (Eculizumab) As A Treatment For Patients With Refractory Generalized Myasthenia Gravis (gMG)

Alexion Submits U.S. And EU Applications Seeking Approval Of Soliris® (Eculizumab) As A Treatment For Patients With Refractory Generalized Myasthenia Gravis (gMG)

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that the Company has submitted marketing applications to the U.